ReviewMaternal-fetal medicine (Wolters Kluwer Health, Inc.)2026
Advancements in Liquid Biopsy Technologies for Non-Invasive Detection of Placental Dysfunction and Perinatal Complications: Focus on cfDNA, cfRNA, and Extracellular Vesicles.
Review in Maternal-fetal medicine (Wolters Kluwer Health, Inc.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Regulatory T cells in pregnancy disorders: a multi-dimensional framework for biomarkers and therapeutic strategies.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advent of liquid biopsy technologies has revolutionized the non-invasive monitoring of various medical conditions, including complications during pregnancy. Fetal and placental health are crucial to maternal and neonatal outcomes, yet many of the conventional diagnostic techniques for detecting placental dysfunction and perinatal complications, such as preeclampsia, preterm birth, and fetal growth restriction, are invasive or pose a risk to the fetus. Liquid biopsy offers a promising alternative by using biomarkers such as cell-free DNA, cell-free RNA, and extracellular vesicles to provide a non-invasive, real-time, and dynamic assessment of placental and fetal health. This review discusses the advancements in liquid biopsy technologies, with a focus on their potential for early detection, monitoring, and understanding of placental dysfunction and perinatal complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.